Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 28, 2019 - Issue 9
Submit an article Journal homepage
756
Views
13
CrossRef citations to date
0
Altmetric
Review

Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update

Egle RamelyteDepartment of Dermatology, University Hospital of Zurich, Zurich, Switzerland;Faculty of Medicine, University of Zurich, Zurich, Switzerland
,
Reinhard DummerDepartment of Dermatology, University Hospital of Zurich, Zurich, Switzerland;Faculty of Medicine, University of Zurich, Zurich, SwitzerlandCorrespondence[email protected]
&
Emmanuella GuenovaDepartment of Dermatology, University Hospital of Zurich, Zurich, Switzerland;Faculty of Medicine, University of Zurich, Zurich, Switzerland
Pages 799-809 | Received 14 Jun 2019, Accepted 08 Aug 2019, Published online: 18 Aug 2019

  • Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019 Jan 11. PubMed PMID: 30635287. DOI:10.1182/blood-2018-11-881268.
  • Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004 May 6;350(19):1978–1988. PubMed PMID: 15128898. .
  • Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010 Aug 5;116(5):767–771. PubMed PMID: 20484084; PubMed Central PMCID: PMCPMC2918332.
  • Mangold AR, Thompson AK, Davis MD, et al. Early clinical manifestations of Sezary syndrome: A multicenter retrospective cohort study. J Am Acad Dermatol. 2017 Oct;77(4):719–727. PubMed PMID: 28709694.
  • Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005 May 15;105(10):3768–3785. 10.1182/blood-2004-09-3502. PubMed PMID: 15692063.
  • Bruggen MC, Kerl K, Haralambieva E, et al. Aggressive rare T-cell lymphomas with manifestation in the skin: a monocentric cross-sectional case study. Acta Derm Venereol. 2018 Oct 10;98(9):835–841. PubMed PMID: 29693696.
  • Guenova E, Schanz S, Hoetzenecker W, et al. Systemic corticosteroids for subcutaneous panniculitis-like T-cell lymphoma. Br J Dermatol. 2014 Oct;171(4):891–894. PubMed PMID: 24725144.
  • Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014 Feb;70(2):205 e1–16; quiz 221–2. PubMed PMID: 24438969.
  • Guenova E, Watanabe R, Teague JE, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res. 2013 Jul 15;19(14):3755–3763. PubMed PMID: 23785046; PubMed Central PMCID: PMCPMC3715586.
  • Lessin SR, Vowels BR, Rook AH. Th2 cytokine profile in cutaneous T-cell lymphoma. J Invest Dermatol. 1995 Dec;105(6):855–856. PubMed PMID: 7490483.
  • Dummer R, Heald PW, Nestle FO, et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood. 1996 Aug 15;88(4):1383–1389. PubMed PMID: 8695857.
  • Krejsgaard T, Lindahl LM, Mongan NP, et al. Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol. 2017 Apr;39(3):269–282. PubMed PMID: 27717961; PubMed Central PMCID: PMCPMC5368200.
  • Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res. 2012 Sep 15;18(18):5051–5060. CCR-12-0604. PubMed PMID: 22850569; PubMed Central PMCID: PMCPMC3857608.
  • Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2018 Sep 29. PubMed PMID: 30267549. DOI:10.1111/bjd.17258.
  • Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015 Nov 10;33(32):3766–3773. PubMed PMID: 26438120; PubMed Central PMCID: PMCPMC4979132.
  • Trautinger F, Eder J, Assaf C, et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - Update 2017. Eur J Cancer. 2017 May;77:57–74. PubMed PMID: 28365528.
  • DeSimone JA, Sodha P, Ignatova D, et al. Recent advances in primary cutaneous T-cell lymphoma. Curr Opin Oncol. 2015 Mar;27(2):128–133. PubMed PMID: 25594623.
  • Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the cutaneous lymphoma international consortium. Ann Oncol. 2019 Mar 1;30(3):494. PubMed PMID: 29947731.
  • Mempel M, Kalali BN, Ollert M, et al. Toll-like receptors in dermatology. Dermatol Clin. 2007 Oct;25(4):531–40, viii. PubMed PMID: 17903612.
  • Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the drosophila toll protein signals activation of adaptive immunity. Nature. 1997 Jul 24;388(6640):394–397. PubMed PMID: 9237759. .
  • Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005 Feb 1;174(3):1259–1268. PubMed PMID: 15661881.
  • Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst. 2005 Aug 3;97(15):1143–1153. PubMed PMID: 16077073.
  • Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med. 2009 Aug 31;206(9):1983–1994. PubMed PMID: 19703986; PubMed Central PMCID: PMCPMC2737167.
  • Dummer R, Urosevic M, Kempf W, et al. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology. 2003;207(1):116–118. PubMed PMID: 12835571 .
  • Shalabi D, Bistline A, Alpdogan O, et al. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sezary syndrome (SS). Chin Clin Oncol. 2019 Feb;8(1):11. PubMed PMID: 30691274.
  • Rook AH, Gelfand JM, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015 Sep 17;126(12):1452–1461. PubMed PMID: 26228486; PubMed Central PMCID: PMCPMC4573868.
  • Gul N, van Egmond M. Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res. 2015 Dec 1;75(23):5008–5013. PubMed PMID: 26573795. .
  • Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013 Sep 13;341(6151):1192–1198. PubMed PMID: 24031011. .
  • Rogers LM, Veeramani S, Weiner GJ. Complement in monoclonal antibody therapy of cancer. Immunol Res. 2014 Aug;59(1–3):203–210. PubMed PMID: 24906530; PubMed Central PMCID: PMCPMC4381956. .
  • Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015 Jun;15(6):321–333. PubMed PMID: 25998712; PubMed Central PMCID: PMCPMC4859809. .
  • Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005 Jan 14;120(1):15–20. PubMed PMID: 15652477. .
  • Tili E, Michaille JJ, Wernicke D, et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4908–4913. PubMed PMID: 21383199; PubMed Central PMCID: PMCPMC3064319.
  • O’Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med. 2008 Mar 17;205(3):585–594. PubMed PMID: 18299402; PubMed Central PMCID: PMCPMC2275382.
  • El-Khazragy N, Noshi MA, Abdel-Malak C, et al. miRNA-155 and miRNA-181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia. J Cell Biochem. 2019 Apr;120(4):6315–6321. PubMed PMID: 30362157.
  • Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005 Oct;207(2):243–249. PubMed PMID: 16041695.
  • Ralfkiaer U, Lindahl LM, Litman T, et al. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. Anticancer Res. 2014 Dec;34(12):7207–7217. PubMed PMID: 25503151.
  • Fava P, Bergallo M, Astrua C, et al. miR-155 expression in primary cutaneous T-Cell Lymphomas (CTCL). J Eur Acad Dermatol Venereol. 2017 Jan;31(1):e27–e29. PubMed PMID: 26935979.
  • Seto AG, Beatty X, Lynch JM, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018 Nov;183(3):428–444. PubMed PMID: 30125933. .
  • Matlung HL, Szilagyi K, Barclay NA, et al. The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017 Mar;276(1):145–164. PubMed PMID: 28258703.
  • Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010 Sep 3;142(5):699–713. PubMed PMID: 20813259; PubMed Central PMCID: PMCPMC2943345.
  • Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662–6667. PubMed PMID: 22451913; PubMed Central PMCID: PMCPMC3340046.
  • Querfeld C, Thompson J, Taylor M, et al. A single direct intratumoral injection of TTI-621 (SIRPαFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and sézary syndrome: preliminary findings employing an immune checkpoint inhibitor blocking the CD47 “Do Not Eat” signal. Blood. 2017;130(Suppl 1):4076.
  • Chan AT, Kollnberger SD, Wedderburn LR, et al. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum. 2005 Nov;52(11):3586–3595. PubMed PMID: 16255049.
  • Poszepczynska-Guigne E, Schiavon V, D’Incan M, et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol. 2004 Mar;122(3):820–823. PubMed PMID: 15086570.
  • Battistella M, Leboeuf C, Ram-Wolff C, et al. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Blood. 2017 Dec 28;130(26):2900–2902. PubMed PMID: 29089310.
  • Hurabielle C, Thonnart N, Ram-Wolff C, et al. Usefulness of KIR3DL2 to diagnose, follow-up, and manage the treatment of patients with sezary syndrome. Clin Cancer Res. 2017 Jul 15;23(14):3619–3627. 10.1158/1078-0432.CCR-16-3185. PubMed PMID: 28119365.
  • Marie-Cardine A, Viaud N, Thonnart N, et al. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res. 2014 Nov 1;74(21):6060–6070. PubMed PMID: 25361998.
  • Bagot M, Porcu P, Ram-Wolff C, et al. Phase I study of IPH4102, anti-KIR3DL2 mab, in relapsed/refractory cutaneous T-cell lymphomas (CTCL): dose-escalation safety, biomarker and clinical activity results. Blood. 2017;35(S2):48–49.
  • Bagot M, Porcu P, Marie-Cardine A, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019 Jun 25. PubMed PMID: 31253572. DOI:10.1016/S1470-2045(19)30320-1
  • Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell. 1993 Apr 9;73(1):5–8. PubMed PMID: 8462103.
  • vanderSpek JC, Mindell JA, Finkelstein A, et al. Structure/function analysis of the transmembrane domain of DAB389-interleukin-2, an interleukin-2 receptor-targeted fusion toxin. The amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic domain to the cytosol of target cells. J Biol Chem. 1993 Jun 5;268(16):12077–12082. PubMed PMID: 8505330.
  • Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870–1877. PubMed PMID: 20212249.
  • Ohmachi K, Ando K, Ogura M, et al. E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study. Cancer Sci. 2018 Mar;109(3):794–802. PubMed PMID: 29363235; PubMed Central PMCID: PMCPMC5834772.
  • Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010 May;11(5):329–341. PubMed PMID: 20379207.
  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–674. PubMed PMID: 21376230. .
  • Kaneda MM, Messer KS, Ralainirina N, et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature. 2016 Nov 17;539(7629):437–442. PubMed PMID: 27642729; PubMed Central PMCID: PMCPMC5479689.
  • Duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) 2018 [cited 2019]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/duvelisib-copiktra-verastem-inc-adult-patients-relapsed-or-refractory-chronic-lymphocytic-leukemia
  • Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018 Feb 22;131(8):888–898. PubMed PMID: 29233821; PubMed Central PMCID: PMCPMC5824337.
  • Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998 Feb;22(2):185–191. PubMed PMID: 9593475.
  • Frampton JE, Wagstaff AJ. Alemtuzumab. Drugs. 2003;63(12):1229–43; discussion 1245–6. PubMed PMID: 12790693. .
  • Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003 Jun 1;101(11):4267–4272. PubMed PMID: 12543862.
  • Stewart JR, Desai N, Rizvi S, et al. Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sezary syndrome: a systematic review. Eur J Dermatol. 2018 Dec 1;28(6):764–774. PubMed PMID: 30591425.
  • Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993 Jul 2;73(7):1349–1360. PubMed PMID: 8391931.
  • Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and sternberg-reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982 Sep 2;299(5878):65–67. PubMed PMID: 7110326.
  • Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985 Oct;66(4):848–858. PubMed PMID: 3876124.
  • Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res off J Am Assoc Cancer Res. 2009 Oct 1;15(19):6217–6224. PubMed PMID: 19789316.
  • Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015 Nov 10;33(32):3750–3758. PubMed PMID: 26195720; PubMed Central PMCID: PMCPMC5089160. Author contributions are found at the end of this article: www.jco.org.
  • Prince HM, YH K, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555–566. PubMed PMID: 28600132.
  • FDA. 2017. Accessed 15 May, 2019. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584543.htm.
  • EMA. 2017. Acessed 15 May, 2019. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002455/smops/Positive/human_smop_001229.jsp&mid=WC0b01ac058001d127.
  • Wang L, Ni X, Covington KR, et al. Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet. 2015 Dec;47(12):1426–1434. PubMed PMID: 26551670; PubMed Central PMCID: PMCPMC4829974.
  • Andrew DP, Ruffing N, Kim CH, et al. C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential. J Immunol. 2001 Jan 1;166(1):103–111. PubMed PMID: 11123282.
  • Kakinuma T, Sugaya M, Nakamura K, et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol. 2003 Jan;48(1):23–30. PubMed PMID: 12522366.
  • Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015 Mar 19;125(12):1883–1889. PubMed PMID: 25605368; PubMed Central PMCID: PMCPMC4375715.
  • Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 Sep;19(9):1192–1204. PubMed PMID: 30100375.
  • FDA approves mogamulizumab-kpkc for mycosis fungoides or Sézary syndrome. 2018. Acessed 15 May, 2019. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mogamulizumab-kpkc-mycosis-fungoides-or-sezary-syndrome.
  • Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000 Oct 2;192(7):1027–1034. PubMed PMID: 11015443; PubMed Central PMCID: PMCPMC2193311.
  • Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009 May;229(1):114–125. PubMed PMID: 19426218; PubMed Central PMCID: PMCPMC3424066. .
  • Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017 Jan 18;541(7637):321–330. PubMed PMID: 28102259. .
  • Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1480–1492. PubMed PMID: 30361170.
  • Querfeld C, Leung S, Myskowski PL, et al. Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile. Cancer Immunol Res. 2018 Aug;6(8):900–909. PubMed PMID: 29895574; PubMed Central PMCID: PMCPMC6074045.
  • Wartewig T, Kurgyis Z, Keppler S, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017 Dec 7;552(7683):121–125. PubMed PMID: 29143824; PubMed Central PMCID: PMCPMC5821214.
  • Barta SK, Zain J, MacFarlane AWT, et al. Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2019 Apr 3. PubMed PMID: 31029646. DOI:10.1016/j.clml.2019.03.022.
  • Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016 Aug 10;34(23):2698–2704. PubMed PMID: 27269947; PubMed Central PMCID: PMCPMC5019749. . Author contributions are found at the end of this article: www.jco.org.
  • Khodadoust M, Rook AH, Porcu P, et al. Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a citn multicenter phase 2 study. Blood. 2016;128(22):181.
  • Pelner L, Fowler GA, Nauts HC. Effects of concurrent infections and their toxins on the course of leukemia. Acta Med Scand Suppl. 1958;338:1–47. PubMed PMID: 13605619.
  • Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007 Apr;15(4):651–659. PubMed PMID: 17299401. .
  • Heinzerling L, Kunzi V, Oberholzer PA, et al. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood. 2005 Oct 1;106(7):2287–2294. 10.1182/blood-2004-11-4558. PubMed PMID: 15961518.
  • Kaplan EH, Rosen ST, Norris DB, et al. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990 Feb 7;82(3):208–212. PubMed PMID: 2104937.
  • Dummer R, Hassel JC, Fellenberg F, et al. Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomas. J Blood. 2004;104(6):1631–1638.
  • Dummer R, Eichmuller S, Gellrich S, et al. Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther. 2010 Jun;18(6):1244–1247. PubMed PMID: 20372104; PubMed Central PMCID: PMCPMC2889748.
  • Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015 Sep 1;33(25):2780–2788. PubMed PMID: 26014293.
  • Rupoli S, Goteri G, Pulini S, et al. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol. 2005 Aug;75(2):136–145. PubMed PMID: 16000130.
  • Anzengruber F, Ignatova D, Schlaepfer T, et al. Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sezary syndrome. Leuk Lymphoma. 2019 Aug;60(8):1899–1907. PubMed PMID: 30638415.
  • Ralfkiaer U, Hagedorn PH, Bangsgaard N, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 2011 Nov 24;118(22):5891–5900. PubMed PMID: 21865341; PubMed Central PMCID: PMCPMC3342856.
  • Zhang XH, Nam S, Wu J, et al. Multi-Kinase inhibitor with anti-p38gamma activity in cutaneous T-cell lymphoma. J Invest Dermatol. 2018 Nov;138(11):2377–2387. PubMed PMID: 29758280.
  • Gallardo F, Bertran J, Lopez-Arribillaga E, et al. Novel phosphorylated TAK1 species with functional impact on NF-kappaB and beta-catenin signaling in human Cutaneous T-cell lymphoma. Leukemia. 2018 Oct;32(10):2211–2223. PubMed PMID: 29511289; PubMed Central PMCID: PMCPMC6170395.
  • Kohnken R, McNeil B, Wen J, et al. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma. J Invest Dermatol. 2019 Mar 12. PubMed PMID: 30876800. DOI:10.1016/j.jid.2019.01.033.
  • Froehlich TC, Muller-Decker K, Braun JD, et al. Combined inhibition of Bcl-2 and NFkappaB synergistically induces cell death and limits xenograft mouse tumor growth in CTCL. Blood. 2019 Jun 5. PubMed PMID: 31167801. DOI: 10.1182/blood.2019001545.
  • Jumbou O, N’Guyen JM, Tessier MH, et al. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol. 1999 Mar;140(3):427–431. PubMed PMID: 10233261.
  • Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006 Jul;7(1):51–58. PubMed PMID: 16879770.
  • Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000 Jul;18(13):2603–2606. PubMed PMID: 10893292.
  • O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182–1189. PubMed PMID: 21245435; PubMed Central PMCID: PMCPMC3083873.
  • Foss F, Horwitz SM, Coiffier B, et al. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):238–243. PubMed PMID: 22542448.
  • Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003 Nov;49(5):873–878. PubMed PMID: 14576667. .
  • Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001 May 1;19(9):2456–2471. PubMed PMID: 11331325.
  • Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007 Jan 1;109(1):31–39. PubMed PMID: 16960145; PubMed Central PMCID: PMCPMC1785068.
  • Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010 Oct 10;28(29):4485–4491. PubMed PMID: 20697094.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.